Given this background, MR antagonists spironolactone and eplerenone have been employed in pilot studies for treating patients with CSC with encouraging results [18]; however, some limitations are present with this class of drugs: close monitoring of renal function and potassium levels should be performed before starting therapy with MR antagonists, considering the risks such as cardiac arrhythmia associated with hyperkalemia. This evidence concerns the gene NR3C2 and cardiac rhythm disease.